Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Brat (Brno, Czech Republic), M. Bratova (Brno, Czech Republic), J. Skrickova (Brno, Czech Republic), M. Barinova (Brno, Czech Republic), K. Hurdalkova (Brno, Czech Republic), M. Pesek (Pilsen, Czech Republic), M. Svaton (Pilsen, Czech Republic), L. Havel (Prague, Czech Republic), M. Cernovska (Prague, Czech Republic), L. Koubkova (Prague, Czech Republic), M. Hrnciarik (Hradec Kralove, Czech Republic), J. Krejci (Prague, Czech Republic), J. Kultan (Olomouc, Czech Republic), O. Fischer (Olomouc, Czech Republic), M. Zemanova (Prague, Czech Republic), H. Coupkova (Brno, Czech Republic), T. Tuzova (Jihlava, Czech Republic), D. Dolezal (Usti nad Labem, Czech Republic), M. Safanda (Prague, Czech Republic). Real-life effectiveness of first-line treatments in NSCLC patients stage IIIB/IV– data from the Czech TULUNG Registry.. 1683

Member's Comments

No comment yet.

Related content which might interest you: Use of erlotinib in management of advanced non-small cell lung cancer (NSCLC): The Czech Republic experience with the treatment of a non-selected population of 1735 patients (pts) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 Characteristics of lung cancer patients in Serbia and subsequent treatment in advanced NSCLC over time – epidemiology study Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Pemetrexed in the first line treatment in non-small cell lung cancer (NSCLC): A multicentre prospective analysis of data from clinical practise of Czech Republic Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Efficacy and safety of nivolumab in routine NSCLC treatment – an observational study in 5 lung cancer centers in Berlin, Germany Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Assessment of costs and outcomes of chemotherapy in an observational setting in patients with advanced NSCLC (ACTION) Source: Eur Respir J 2004; 24: Suppl. 48, 304s Year: 2004 Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care. Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Palliative chemotherapy in non-small cell lung cancer (NSCLC): first-line therapy data from the ACTION observational study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic. Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Clinical trials in advanced stage lung cancer: A survey of patients‘ opinion about their treatment Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients Year: 2010 Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002 CompERA-XL: International, prospective registry for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 Impact of early weight loss during concurrent chemoradiotherapy on survival in advanced stage NSCLC patients Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Pulmonary function during lung cancer therapy: A retrospective analysis of patients treated with monotherapy or multimodal treatments Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016